我国新的和严重的药品不良反应报告现状及障碍分析  

Status and Barriers of New and Serious ADR Reports in China

作　　者：王文沛[1] 邵蓉[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药事》2011年第3期227-230,共4页Chinese Pharmaceutical Affairs

摘　　要：目的了解我国新的和严重的药品不良反应报告工作面临的障碍,促进有关部门做好此类报告工作。方法采用文献研究和比较研究的方法,了解国内外对新的、严重的药品不良反应报告制度的相关规定,分析我国此类报告工作存在障碍的成因。结果与结论社会发展阶段制约、报告主体认知度低、制度不健全、报告途径受阻等是这类报告比例偏低的根本原因,需要从以上方面着手改善。Objective To understand the barriers of new and serious adverse drug reaction reporting in our country,and promote the work of relevant departments such reports.Methods Literature review and comparative study were used to understand the relevant provisions of the new and serious ADR reporting system in home and abroad,and analyze the causes existing obstacles.Results and Conclusion Constraints of stage of social development,low awareness of the reporting entity,system distemperedness and report approach suffocated are the root causes by the low percentage report rate.The above aspects need to improve.

关 键 词：药品不良反应报告 新的和严重的 障碍 

分 类 号：R95[医药卫生—药学] R994.11